Certain NSCLC Subgroups May Not Benefit From Immunotherapy

A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.
Medscape Medical News

source https://www.medscape.com/viewarticle/998535?src=rss